2015
Targeting glucose metabolism in cancer: a new class of agents for loco-regional and systemic therapy of liver cancer and beyond?
Savic LJ, Chapiro J, Duwe G, Geschwind J. Targeting glucose metabolism in cancer: a new class of agents for loco-regional and systemic therapy of liver cancer and beyond? Hepatic Oncology 2015, 3: 19-28. PMID: 26989470, PMCID: PMC4792180, DOI: 10.2217/hep.15.36.Peer-Reviewed Original ResearchIntra-arterial therapyHepatocellular carcinomaCancer-related deathUnresectable diseaseCancer cell metabolismSystemic therapyTherapeutic optionsTumor controlPrevalent cancerLiver cancerGlucose metabolismAntiglycolytic agentsTumor growthSystemic toxicitySelective anticancer therapyTherapyAnticancer therapyCancerNew targetsWarburg effectMolecular featuresAntiglycolytic drugsCell metabolismDelivery methodsMetabolism
2014
Combination of intra-arterial therapies and sorafenib: Is there a clinical benefit?
Chapiro J, Duran R, Geschwind JF. Combination of intra-arterial therapies and sorafenib: Is there a clinical benefit? La Radiologia Medica 2014, 119: 476-482. PMID: 24894921, DOI: 10.1007/s11547-014-0413-0.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsBiomarkers, TumorCarcinoma, HepatocellularChemoembolization, TherapeuticEmbolization, TherapeuticHepatectomyHepatic ArteryHumansInfusions, Intra-ArterialLiver NeoplasmsMicrospheresNeoplasm StagingNiacinamidePhenylurea CompoundsRadiography, InterventionalSorafenibSurvival RateConceptsIntra-arterial therapySurvival benefitIntroduction of sorafenibLoco-regional approachesAdvanced stage diseaseSignificant survival benefitUnresectable hepatocellular carcinomaLocal tumor controlTreatment of patientsSequence of administrationConventional systemic chemotherapyInternational clinical trialsOral monotherapySystemic chemotherapyExciting new optionsClinical outcomesTransarterial chemoembolizationClinical benefitSafety profileTumor controlClinical trialsHepatocellular carcinomaNovel agentsPotential biomarkersSystemic toxicity
2013
Percutaneous therapies of hepatocellular carcinoma—an update
Chapiro J, Geschwind JF. Percutaneous therapies of hepatocellular carcinoma—an update. Chinese Clinical Oncology 2013, 2: 36-36. PMID: 25841915, DOI: 10.3978/j.issn.2304-3865.2013.07.04.Peer-Reviewed Original ResearchIntra-arterial therapyHepatocellular carcinomaSpecific therapeutic algorithmsAvailable clinical evidenceEarly-stage diseaseIntra-arterial approachEnd-stage diseaseLocal tumor controlPrimary liver cancerTreatment of patientsTherapeutic algorithmEthanol ablationTransarterial chemoembolizationClinical evidencePatient groupTumor controlPercutaneous techniquesRadiofrequency ablationSuch therapyTherapeutic spectrumAblative techniquesPercutaneous therapyLiver cancerSystemic toxicityTherapyIntraarterial therapies for primary liver cancer: state of the art
Chapiro J, Tacher V, Geschwind JF. Intraarterial therapies for primary liver cancer: state of the art. Expert Review Of Anticancer Therapy 2013, 13: 1157-1167. PMID: 24099626, DOI: 10.1586/14737140.2013.845528.Peer-Reviewed Original ResearchConceptsPrimary liver cancerTreatment of patientsIntraarterial therapyHepatocellular carcinomaLiver cancerIntermediate-stage diseaseOfficial treatment guidelinesAvailable clinical evidenceEffective local tumor controlLocal tumor controlReduced systemic toxicityIntraarterial approachStage diseaseTransarterial chemoembolizationTreatment guidelinesClinical evidenceHepatic malignanciesTumor controlSystemic toxicityTherapyScientific rationalePatientsCancerTreatmentChemoembolization